SAGE Therapeutics (SAGE) Earns Buy Rating from Analysts at Oppenheimer

Share on StockTwits

Oppenheimer initiated coverage on shares of SAGE Therapeutics (NASDAQ:SAGE) in a research note released on Wednesday, Marketbeat.com reports. The brokerage issued a buy rating and a $170.00 price objective on the biopharmaceutical company’s stock.

SAGE has been the topic of a number of other reports. BidaskClub downgraded shares of SAGE Therapeutics from a sell rating to a strong sell rating in a research note on Tuesday, June 19th. Canaccord Genuity set a $220.00 price target on shares of SAGE Therapeutics and gave the stock a buy rating in a research note on Wednesday, August 8th. Piper Jaffray Companies assumed coverage on shares of SAGE Therapeutics in a research note on Monday, August 6th. They issued an overweight rating and a $206.00 price target on the stock. Stifel Nicolaus upped their price target on shares of SAGE Therapeutics from $198.00 to $239.00 and gave the stock a buy rating in a research note on Tuesday, August 7th. Finally, Morgan Stanley upped their price target on shares of SAGE Therapeutics from $225.00 to $228.00 and gave the stock an overweight rating in a research note on Friday, July 13th. Two analysts have rated the stock with a sell rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. SAGE Therapeutics presently has an average rating of Buy and a consensus price target of $204.50.

Shares of NASDAQ SAGE traded up $5.03 during mid-day trading on Wednesday, reaching $124.82. The company had a trading volume of 389,900 shares, compared to its average volume of 495,274. SAGE Therapeutics has a twelve month low of $59.57 and a twelve month high of $195.97. The company has a market capitalization of $6.59 billion, a PE ratio of -17.61 and a beta of 2.92.

SAGE Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.84) by $1.48. The company had revenue of $90.00 million during the quarter. Analysts anticipate that SAGE Therapeutics will post -7.37 EPS for the current fiscal year.

A number of large investors have recently modified their holdings of SAGE. Prudential Financial Inc. boosted its holdings in SAGE Therapeutics by 9.5% in the first quarter. Prudential Financial Inc. now owns 4,220 shares of the biopharmaceutical company’s stock worth $680,000 after purchasing an additional 366 shares in the last quarter. Great West Life Assurance Co. Can boosted its holdings in SAGE Therapeutics by 24.6% in the first quarter. Great West Life Assurance Co. Can now owns 5,186 shares of the biopharmaceutical company’s stock worth $837,000 after purchasing an additional 1,024 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in SAGE Therapeutics by 58.1% in the first quarter. Dimensional Fund Advisors LP now owns 46,362 shares of the biopharmaceutical company’s stock worth $7,468,000 after purchasing an additional 17,044 shares in the last quarter. BNP Paribas Arbitrage SA boosted its holdings in SAGE Therapeutics by 22.9% in the first quarter. BNP Paribas Arbitrage SA now owns 9,698 shares of the biopharmaceutical company’s stock worth $1,562,000 after purchasing an additional 1,804 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its holdings in SAGE Therapeutics by 3.2% in the first quarter. Principal Financial Group Inc. now owns 12,406 shares of the biopharmaceutical company’s stock worth $1,998,000 after purchasing an additional 382 shares in the last quarter.

SAGE Therapeutics Company Profile

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).

Read More: Find a Trading Strategy That Works

Analyst Recommendations for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply